139571-18-9

Upstream product

• 139627-93-3 (2R,4S)-5-<(tert-butyldimethylsilyl)oxy>-2,4-dimethyl-pentanal 
• 139627-94-4 (2S,4R)-5-Hydroxy-2,4-dimethyl-pentanoic acid methyl ester 
• 82917-26-8 [2R,4S]-5-hydroxy-2,4-dimethyl-pentanoic acid methyl ester 
• 157733-60-3 (2S,4R)-methyl 5-benzyloxy-2,4-dimethyl-pentanoate 
• 157733-61-4 (2'R,4'S)-<5'-<(tert-butyldimethylsilyl)oxy>-2',4'-dimethyl-pentyloxymethyl>benzene 
• 157810-31-6 (2S,4R)-5-(benzyloxy)-2,4-dimethylpentan-1-ol 
• 157733-59-0 [2R,4S]-5-(tert-butyl-dimethyl-silanyloxy)-2,4-dimethyl-pentanoic acid methyl ester 
• 69739-34-0 t-butyldimethylsiyl triflate 

Downstream Products

• 157733-72-7 tert-Butyl-((2S,4S)-2,4-dimethyl-8-{2-[(R)-4-(toluene-4-sulfonylmethyl)-hexyl]-[1,3]dioxolan-2-yl}-octyloxy)-dimethyl-silane 
• 139571-19-0 (2S,4S)-2,4-Dimethyl-8-{2-[(R)-4-(toluene-4-sulfonylmethyl)-hexyl]-[1,3]dioxolan-2-yl}-octan-1-ol 

Relevant academic research and scientific papers

A Highly Convergent Total Synthesis of (+)-Myxovirescine M2

The antibiotic myxovirescine M2 was synthesized from seven building blocks (1-7, Scheme 1), with the following chiral starting materials being employed : (S)-malic acid, (+)-D-ribonolactone, (S)-2-(hydroxymethyl)butanoate, and (2R,4S)-5-hydroxy